Investors News Releases Sign up for email alerts to receive company and investor updates News Releases Investor Relations Investor Relations News Releases Presentations & Events Common Stock Information Stock Quote & Chart Analyst Coverage SEC Filings Corporate Governance Overview Board of Directors Committee Composition Management Team Annual Reports News Releases Year None2024202320222021202020192018201720162015201420132012201120102009200820072006 Sep 21 2017 Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2017 Healthcare Conference Sep 08 2017 Cyclacel Pharmaceuticals to Present at the 19th Annual Rodman & Renshaw Global Investment Conference Aug 09 2017 Cyclacel Pharmaceuticals Reports Second Quarter 2017 Financial Results Aug 07 2017 Cyclacel Announces Selection of Recommended Phase 2 Dose for CYC065 and Evidence of Durable Target Engagement and Mcl-1 Biomarker Suppression Aug 02 2017 Cyclacel Pharmaceuticals to Release Second Quarter 2017 Financial Results Jul 21 2017 Cyclacel Announces Closing of $15.2 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option Jul 19 2017 Cyclacel Announces Pricing of $13.2 Million Underwritten Public Offering May 11 2017 Cyclacel Pharmaceuticals Reports First Quarter 2017 Financial Results May 05 2017 Cyclacel Pharmaceuticals to Release First Quarter 2017 Financial Results Apr 04 2017 Cyclacel Presents Identification of Sensitive Target Indications and Synergistic Drug Combinations for Novel PLK1 Inhibitor CYC140 Apr 02 2017 Cyclacel's Second-Generation CDK2/9 Inhibitor, CYC065, Elicits Marked Antineoplastic Effects in Lung Cancer by Engaging Anti-Metastatic Pathways Mar 28 2017 Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results Mar 21 2017 Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2016 Financial Results Mar 07 2017 Cyclacel's CDK Inhibitor CYC065 Causes Anaphase Catastrophe, a Novel Cancer-Specific Mechanism of Action, in Research Published in JNCI Feb 23 2017 Cyclacel Announces Top-Line Results From Pivotal Phase 3 SEAMLESS Study in Elderly Patients With Acute Myeloid Leukemia Feb 06 2017 Cyclacel Pharmaceuticals to Present at the 19th Annual BIO CEO & Investor Conference Dec 01 2016 Cyclacel's Novel PLK1 Inhibitor, CYC140, Demonstrates Therapeutic Potential in Esophageal Cancer and Acute Leukemia Dec 01 2016 EORTC-NCI-AACR 2016. Abstract 355: Therapeutic potential of novel PLK1 inhibitor, CYC140, in esophageal cancer and acute leukemia Nov 14 2016 Cyclacel Pharmaceuticals Reports 3rd Quarter 2016 Financial Results Nov 07 2016 Cyclacel Pharmaceuticals to Release Third Quarter 2016 Financial Results Sep 06 2016 Cyclacel's CYC065 Demonstrates Promising Activity in MYCN-Addicted Neuroblastoma in Preclinical Data Presented at Childhood Cancer 2016 Aug 10 2016 Cyclacel Pharmaceuticals Reports 2nd Quarter 2016 Financial Results Aug 03 2016 Cyclacel Pharmaceuticals to Release Second Quarter 2016 Financial Results Aug 02 2016 Cyclacel's CYC065 Demonstrates Promising Activity in Uterine Serous Carcinoma in Preclinical Data Published by Independent Academic Researchers Jun 16 2016 Cyclacel Regains Compliance With Nasdaq Continued Listing Requirements Pagination First page « first Previous page ‹ previous … Page 3 Page 4 Page 5 Page 6 Current page 7 Page 8 Page 9 Page 10 Page 11 … Next page next › Last page last » Toolkit Email AlertsRSS FeedsPrint Page
News Releases Year None2024202320222021202020192018201720162015201420132012201120102009200820072006 Sep 21 2017 Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2017 Healthcare Conference Sep 08 2017 Cyclacel Pharmaceuticals to Present at the 19th Annual Rodman & Renshaw Global Investment Conference Aug 09 2017 Cyclacel Pharmaceuticals Reports Second Quarter 2017 Financial Results Aug 07 2017 Cyclacel Announces Selection of Recommended Phase 2 Dose for CYC065 and Evidence of Durable Target Engagement and Mcl-1 Biomarker Suppression Aug 02 2017 Cyclacel Pharmaceuticals to Release Second Quarter 2017 Financial Results Jul 21 2017 Cyclacel Announces Closing of $15.2 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option Jul 19 2017 Cyclacel Announces Pricing of $13.2 Million Underwritten Public Offering May 11 2017 Cyclacel Pharmaceuticals Reports First Quarter 2017 Financial Results May 05 2017 Cyclacel Pharmaceuticals to Release First Quarter 2017 Financial Results Apr 04 2017 Cyclacel Presents Identification of Sensitive Target Indications and Synergistic Drug Combinations for Novel PLK1 Inhibitor CYC140 Apr 02 2017 Cyclacel's Second-Generation CDK2/9 Inhibitor, CYC065, Elicits Marked Antineoplastic Effects in Lung Cancer by Engaging Anti-Metastatic Pathways Mar 28 2017 Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results Mar 21 2017 Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2016 Financial Results Mar 07 2017 Cyclacel's CDK Inhibitor CYC065 Causes Anaphase Catastrophe, a Novel Cancer-Specific Mechanism of Action, in Research Published in JNCI Feb 23 2017 Cyclacel Announces Top-Line Results From Pivotal Phase 3 SEAMLESS Study in Elderly Patients With Acute Myeloid Leukemia Feb 06 2017 Cyclacel Pharmaceuticals to Present at the 19th Annual BIO CEO & Investor Conference Dec 01 2016 Cyclacel's Novel PLK1 Inhibitor, CYC140, Demonstrates Therapeutic Potential in Esophageal Cancer and Acute Leukemia Dec 01 2016 EORTC-NCI-AACR 2016. Abstract 355: Therapeutic potential of novel PLK1 inhibitor, CYC140, in esophageal cancer and acute leukemia Nov 14 2016 Cyclacel Pharmaceuticals Reports 3rd Quarter 2016 Financial Results Nov 07 2016 Cyclacel Pharmaceuticals to Release Third Quarter 2016 Financial Results Sep 06 2016 Cyclacel's CYC065 Demonstrates Promising Activity in MYCN-Addicted Neuroblastoma in Preclinical Data Presented at Childhood Cancer 2016 Aug 10 2016 Cyclacel Pharmaceuticals Reports 2nd Quarter 2016 Financial Results Aug 03 2016 Cyclacel Pharmaceuticals to Release Second Quarter 2016 Financial Results Aug 02 2016 Cyclacel's CYC065 Demonstrates Promising Activity in Uterine Serous Carcinoma in Preclinical Data Published by Independent Academic Researchers Jun 16 2016 Cyclacel Regains Compliance With Nasdaq Continued Listing Requirements Pagination First page « first Previous page ‹ previous … Page 3 Page 4 Page 5 Page 6 Current page 7 Page 8 Page 9 Page 10 Page 11 … Next page next › Last page last »
Sep 08 2017 Cyclacel Pharmaceuticals to Present at the 19th Annual Rodman & Renshaw Global Investment Conference
Aug 07 2017 Cyclacel Announces Selection of Recommended Phase 2 Dose for CYC065 and Evidence of Durable Target Engagement and Mcl-1 Biomarker Suppression
Jul 21 2017 Cyclacel Announces Closing of $15.2 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option
Apr 04 2017 Cyclacel Presents Identification of Sensitive Target Indications and Synergistic Drug Combinations for Novel PLK1 Inhibitor CYC140
Apr 02 2017 Cyclacel's Second-Generation CDK2/9 Inhibitor, CYC065, Elicits Marked Antineoplastic Effects in Lung Cancer by Engaging Anti-Metastatic Pathways
Mar 07 2017 Cyclacel's CDK Inhibitor CYC065 Causes Anaphase Catastrophe, a Novel Cancer-Specific Mechanism of Action, in Research Published in JNCI
Feb 23 2017 Cyclacel Announces Top-Line Results From Pivotal Phase 3 SEAMLESS Study in Elderly Patients With Acute Myeloid Leukemia
Dec 01 2016 Cyclacel's Novel PLK1 Inhibitor, CYC140, Demonstrates Therapeutic Potential in Esophageal Cancer and Acute Leukemia
Dec 01 2016 EORTC-NCI-AACR 2016. Abstract 355: Therapeutic potential of novel PLK1 inhibitor, CYC140, in esophageal cancer and acute leukemia
Sep 06 2016 Cyclacel's CYC065 Demonstrates Promising Activity in MYCN-Addicted Neuroblastoma in Preclinical Data Presented at Childhood Cancer 2016
Aug 02 2016 Cyclacel's CYC065 Demonstrates Promising Activity in Uterine Serous Carcinoma in Preclinical Data Published by Independent Academic Researchers
